Literature DB >> 29892183

Ideal Cure for Hepatitis B Infection: The Target is in Sight.

Shrihari A Anikhindi1,2, Ashish Kumar1,2, Praveen Sharma1,2, Vikas Singla1,2, Naresh Bansal1,2, Anil Arora1,2.   

Abstract

Hepatitis B virus (HBV) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. Despite recent strides in pharmacotherapy, complete cure of HBV infection still remains an enigma. The biggest obstacle in HBV therapy is clearance of covalently closed circular deoxyribonucleic acid (cccDNA). We discuss about the role of cccDNA in HBV life cycle, efficacy and shortcomings of currently available antivirals as well as promising novel targets to achieve ideal HBV cure.

Entities:  

Keywords:  DNA, deoxyribonucleic acid; HBV; HBV, hepatitis B virus; antivirals; ccc, covalently closed circular; cccDNA

Year:  2017        PMID： 29892183      PMCID： PMC5992304          DOI： 10.1016/j.jceh.2017.10.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


  58 in total

Review 1.  The dynamics of the immune response in acute hepatitis B: new lessons using new techniques.

Authors:  M P Curry; M Koziel
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

Review 2.  Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Authors:  Robert G Gish; Man-Fung Yuen; Henry Lik Yuen Chan; Bruce D Given; Ching-Lung Lai; Stephen A Locarnini; Johnson Y N Lau; Christine I Wooddell; Thomas Schluep; David L Lewis
Journal:  Antiviral Res       Date:  2015-06-27       Impact factor: 5.970

Review 3.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

4.  Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.

Authors:  R Idilman; F Gunsar; M Koruk; O Keskin; C E Meral; M Gulsen; A H Elhan; U S Akarca; C Yurdaydin
Journal:  J Viral Hepat       Date:  2014-11-28       Impact factor: 3.728

5.  Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Authors:  Natthaya Chuaypen; Methee Sriprapun; Kesmanee Praianantathavorn; Sunchai Payungporn; Naruemon Wisedopas; Yong Poovorawan; Pisit Tangkijvanich
Journal:  J Med Virol       Date:  2016-06-21       Impact factor: 2.327

6.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.

Authors:  M Tsiang; J F Rooney; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

7.  One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.

Authors:  Danny Ka-Ho Wong; Man-Fung Yuen; Vincent Wing-Shun Ngai; James Fung; Ching-Lung Lai
Journal:  Antivir Ther       Date:  2006

8.  Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.

Authors:  Satoru Hagiwara; Masatoshi Kudo; Yukio Osaki; Hiroo Matsuo; Tadashi Inuzuka; Akihiro Matsumoto; Eiji Tanaka; Toshiharu Sakurai; Kazuomi Ueshima; Tatsuo Inoue; Norihisa Yada; Naoshi Nishida
Journal:  J Med Virol       Date:  2013-06       Impact factor: 2.327

9.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.

Authors:  Jeffrey D Stanaway; Abraham D Flaxman; Mohsen Naghavi; Christina Fitzmaurice; Theo Vos; Ibrahim Abubakar; Laith J Abu-Raddad; Reza Assadi; Neeraj Bhala; Benjamin Cowie; Mohammad H Forouzanfour; Justina Groeger; Khayriyyah Mohd Hanafiah; Kathryn H Jacobsen; Spencer L James; Jennifer MacLachlan; Reza Malekzadeh; Natasha K Martin; Ali A Mokdad; Ali H Mokdad; Christopher J L Murray; Dietrich Plass; Saleem Rana; David B Rein; Jan Hendrik Richardus; Juan Sanabria; Mete Saylan; Saeid Shahraz; Samuel So; Vasiliy V Vlassov; Elisabete Weiderpass; Steven T Wiersma; Mustafa Younis; Chuanhua Yu; Maysaa El Sayed Zaki; Graham S Cooke
Journal:  Lancet       Date:  2016-07-07       Impact factor: 79.321

10.  Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.

Authors:  Kouichi Kitamura; Zhe Wang; Sajeda Chowdhury; Miyuki Simadu; Miki Koura; Masamichi Muramatsu
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823
View more
  2 in total

Review 1.  Mapping the Interactions of HBV cccDNA with Host Factors.

Authors:  Nur K Mohd-Ismail; Zijie Lim; Jayantha Gunaratne; Yee-Joo Tan
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

2.  Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.

Authors:  Ed J Gane; Christian Schwabe; Elina Berliba; Pisit Tangkijvanich; Alina Jucov; Nelea Ghicavii; Thierry Verbinnen; Oliver Lenz; Willem Talloen; Thomas N Kakuda; Chris Westland; Megha Patel; Jeysen Z Yogaratnam; Leonard Dragone; Pieter Van Remoortere
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.